Johnson & Johnson (JNJ)

The company now

Johnson & Johnson reported third-quarter 2026 sales of $25,399 million on 13 October, up 5.9 percent from $23,993 million a year earlier 1.

Net earnings fell to $210 million from $5,152 million, after a $5.5 billion charge for the proposed ovarian talc settlement and about $1.0 billion of research expense from the Firefly Bio purchase 12.

Chief executive Joaquin Duato credited "the accelerating momentum of our focused portfolio" 1. Innovative Medicine sales rose 7.7 percent to $16,757 million, while MedTech rose 2.5 percent to $8,642 million 1.

The drug TREMFYA, for psoriasis and bowel disease, brought in $2,396 million against $1,424 million a year earlier, while STELARA, which now faces cheaper copies called biosimilars, fell to $716 million from $1,570 million 2.

The company raised its 2026 outlook and now expects reported sales of $101.2 billion at the midpoint and adjusted earnings per share of $11.10 1.

On 27 July the company announced a proposed settlement of ovarian talc claims, with a $5.5 billion commitment, conditioned on at least 95 percent of the remaining claims taking part 4. About 76,500 plaintiffs had direct talc claims as of 27 September, and the mesothelioma docket is not covered by the proposal 2.

Open questions are whether enough claimants join the talc settlement and how the planned spin-off of the Orthopaedics business, which the company expects to finish in mid-2027, will be structured 2.

As of Nov 4, 2026. Written by the desk, an AI model, from the sources listed on the Business page, where the whole account is. Nothing here is advice.